DOCSLIB.ORG

BG Newsletter

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BG Newsletter MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE September 2019 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, As we enter the last quarter of the year, fresh data on venture cash +6.5% confirm that 2019 should see a steady amount raised compared to the 5Y-CAGR past four years, but with a falling number of rounds. With $10.2bn raised Worldwide prescription as at the end of September 2019, annual biopharma venture investments will not reach the $17.3bn they achieved in 2018 but will not be far off drugs-expected sales the 2015-2017 average of $10.9bn. Importantly, new VC funding continued to concentrate. The >500 rounds in 2015 had fallen to 278 by the end of September 2019, while the average funding per round grew from $22m to $38m over the same period. Of note is the fact that VC investors do not seem to be neglecting early-stage assets. However they continue to favour some therapeutic areas, with oncology, which +5.3% accounted for 6 companies in the top 10 VC rounds in 3Q19, still 5Y-CAGR dominating the field. Medtech Private placement activities remained dynamic last month, dominated by market-expected growth UK-based companies in the hotspots of surgical robotics (€220m for CMR Surgical), cancer immunotherapies (€110m for Achilles Therapeutics) or AI-driven drug discovery (€82m for BenevolentAI). We continue to see private placements as a preferred route for the funding of European biopharma companies in the current context of light ECM activity, which saw no IPOs in September and subdued follow-on volumes. Less +1.8% / -8.1% surprisingly for the time of year, M&A has remained light, with only three EU Pharma & Biotech transactions above €100m last month in European healthcare: Sofina’s performance over the €500m bid for Nuxe, Blue Sail Medical’s €145m takeover of New Valve and Sagard’s €100m acquisition of Sterimed. last month From an industry standpoint, the ECTRIMS and ESMO congresses were the two most- watched events in September. At ESMO, the battle between GlaxoSmithKline and AstraZeneca/Merck & Co’s PARP inhibitors dominated the agenda, with GSK making another promising move back into oncology while AZ and Merck show a strong presence in the field. In 20 / $4.9bn biotech, we highlight the strong performance of Seattle Genetics and its Number & total value of Enfortumab combo data in urothelial cancer, and Hong-Kong-based Hutchison Chi-Med with Surufatinib for neuroendocrine tumours. These US ECM deals priced in performances offset failures mostly from US players such as G1 September Therapeutics, Calithera and Aravive, while European biotechs were holding up, including Swiss-based Basilea with further differentiated derazantinib data, and Finnish Faron with clevegen in colorectal cancer. In terms of upcoming sector news flow, we flag the numerous investor updates to be held by year-end, which we believe will further contribute 250 to already a rich year. Sanofi’s investor day on 10 December in Boston will The number of marketed eventually be the main event, with incoming CEO Paul Hudson expected to share his roadmap and R&D head John Reed outlining his plans to US drugs whose price revive R&D. Other major R&D updates include Galapagos (14 November), could be renegotiated Novo Nordisk (5 December), Morphosys (8 December) and Genmab (9 each year under Pelosi’s December). healthcare plan HERVE RONIN 2 Partner | Bryan, Garnier & Co MARKET UPDATE| HEALTHCARE SEPTEMBER AT A GLANCE — FOCUS ON EUROPE ▪ Market volatility was reduced compared to last month on either side of the Atlantic with the VIX and V2X decreasing by 14.4% and 10.4%, respectively EQUITY MARKETS ▪ In September, European and US Biotech stocks plummeted while pharma indices showed a positive performance: ▪ US / EU Biotech perf.: -3.3% / -8.1% ▪ US / EU Pharma perf.: +0.9% / +1.8% ▪ GSK confirms Zejula efficacy with detailed Phase III results in ovarian cancer (OC) ▪ Zejula (PARP inhibitor – niraparib), increased progression INDUSTRY & SCIENCE free survival (+5.6 months) in 1st line OC, regardless of biomarker status ▪ Zejula was initially developed by Tesaro, acquired by GSK in 2018 for $5.1 billion ▪ Inotrem raises €39 million in a Series B led by American venture capital firm Morningside alongside, Invus and historical shareholders Andera, Sofinnova and Biomed Invest FINANCING ▪ Proceeds will be mainly used by Inotrem to conduct the Phase IIb trial of its lead drug nangibotide in septic shock ▪ Bryan, Garnier & Co acted as Sole Financial Advisor to Inotrem on its fundraising process ▪ Blue Sail Medical (China) acquires New Valve Technology AG for a cash consideration of €145 million ▪ New Valve Technology (NVT) is a Swiss-based company developing and selling medical devices for minimally-invasive M&A transcatheter technologies for cardiac valves ▪ NVT markets the Allegra TAVI system and is in the process of getting CE mark for a Valve-in-Valve technology to treat degenerated surgical biological aortic valves ▪ Q3 2019 earnings season: Roche (10/16), Biomerieux (10/22), Novartis (10/22), AstraZeneca (10/24) Ipsen(10/24), NEXT MONTH Bayer (10/30), GSK (10/30), Sanofi (10/31) ▪ Conference and events in October: AAO (10/12-15), ANA (10/13-15), ESGCT (10/22-25) 3 MARKET UPDATE| HEALTHCARE BRYAN, GARNIER & Co 7TH HEALTHCARE CONFERENCE 4 MARKET UPDATE| HEALTHCARE EQUITY MARKETS 1-YEAR PERFORMANCE 3-MONTH PERFORMANCE Nasdaq Eurostoxx Nasdaq Eurostoxx -1% 5% 0% +3% Nasdaq: 7,999 Eurostoxx: 3,569 Sep-18 Dec-18 Mar-19 Jun-19 Sep-19 Jun-19 Jul-19 Aug-19 Sep-19 Pharma US Pharma EUR Pharma US Pharma EUR -1% +13% -2% +6% Pharma US: 587 Pharma EU: 171 Sep-18 Dec-18 Mar-19 Jun-19 Sep-19 Jun-19 Jul-19 Aug-19 Sep-19 Nasdaq Biotech Next Biotech Nasdaq Biotech Next Biotech -18% +5% -9% +3% Nasdaq Biotech: 3,127 Next Biotech: 2,301 Sep-18 Dec-18 Mar-19 Jun-19 Sep-19 Jun-19 Jul-19 Aug-19 Sep-19 VIX V2X VIX Index V2X Index +34% +7% +8% +15% VIX: 16 V2X: 15 Sep-18 Dec-18 Mar-19 Jun-19 Sep-19 Jun-19 Jul-19 Aug-19 Sep-19 5 Source: Bloomberg MARKET UPDATE| HEALTHCARE EURONEXT HEALTHCARE COMPANY PERFORMANCE Pharmaceuticals Performance Company Exchange Mkt Cap (€m) YTD 1 month SANOFI EN Paris 106,508 17.1% 8.9% UCB SA EN Brussels 12,954 -5.0% -2.0% IPSEN EN Paris 7,300 -22.1% -8.9% VIRBAC SA EN Paris 1,776 84.5% 24.6% FAGRON EN Brussels 1,168 14.6% -0.3% VETOQUINOL SA EN Paris 699 16.8% -3.3% BOIRON SA EN Paris 571 -31.1% -13.0% Biotechs Performance Company Exchange Mkt Cap (€m) YTD 1 month GALAPAGOS NV EN Amsterdam 8,661 73.5% -8.9% ARGENX SE EN Brussels 3,924 22.2% -11.9% MITHRA PHARM EN Brussels 1,120 48.6% 8.1% PHARMING GRP NV EN Amsterdam 774 63.2% -0.4% GENFIT EN Paris 571 -15.2% -7.4% DBV TECHNOLOGIES EN Paris 568 48.0% -5.6% INNATE PHARMA SA EN Paris 449 -5.9% 15.8% CELLECTIS EN Paris 401 -37.4% -14.3% VALNEVA SE EN Paris 267 -8.5% -8.4% POXEL SA EN Paris 194 47.0% 21.2% AB SCIENCE SA EN Paris 184 20.7% -1.5% NANOBIOTIX EN Paris 182 -30.2% -4.5% TRANSGENE SA EN Paris 162 -27.1% 9.6% KIADIS PHARM EN Amsterdam 152 -32.8% 6.1% MEDINCELL SA EN Paris 151 12.8% 8.7% NICOX SA EN Paris 149 -0.4% 12.3% CELYAD EN Brussels 124 -46.3% -20.0% OXURION NV EN Brussels 99 -28.3% -12.9% ABIVAX SA EN Paris 93 -33.4% -6.1% ACACIA PHARMA GR EN Brussels 91 33.0% -8.4% ADVICENNE EN Paris 88 14.2% -11.1% QUANTUM GEN-REGR EN Paris 79 -12.0% -11.3% ERYTECH PHARMA EN Paris 77 -31.5% -16.7% ADOCIA SAS EN Paris 75 -34.6% -8.9% PHARNEXT SA EN Paris 75 -52.8% -30.7% VIVORYON THERAPE EN Amsterdam 73 131.6% -7.3% INVENTIVA SA EN Paris 59 -60.3% 9.3% GENEURO SA EN Paris 56 10.2% 6.8% OSE IMMUNO EN Paris 55 7.9% 6.1% ONCODESIGN EN Paris 51 14.1% 2.8% SENSORION SA EN Paris 40 22.3% 3.7% BONE THERAPEUTIC EN Brussels 37 -21.6% -8.3% GENSIGHT EN Paris 35 -63.7% -13.3% ONXEO EN Paris 34 -30.7% -7.4% GENKYOTEX SA EN Paris 29 -64.9% -5.6% ASIT BIOTECH SA EN Brussels 25 -24.7% 17.7% LYSOGENE SA EN Paris 24 10.6% 6.6% PLANT ADVANCED EN Paris 16 5.6% 1.8% Source: Bloomberg 6 (1) Market Cap higher than €15m were selected MARKET UPDATE| HEALTHCARE EURONEXT HEALTHCARE COMPANY PERFORMANCE Medical Products & Devices Performance Company Exchange Mkt Cap (€m) YTD 1 month SARTORIUS STEDIM EN Paris 11,836 47.8% -8.8% BIOMERIEUX EN Paris 8,984 32.6% 2.6% EUROFINS SCIEN EN Paris 7,589 31.7% 2.4% GUERBET EN Paris 584 -9.9% -5.0% ION BEAM APPLICA EN Brussels 475 22.9% -1.4% BIOCARTIS NV EN Brussels 350 -37.6% -40.0% LUMIBIRD EN Paris 256 26.2% -15.6% CARMAT EN Paris 241 -18.3% -7.9% SEQUANA MEDICAL EN Brussels 88 n.a. -0.3% AMPLITUDE SURGIC EN Paris 67 -48.7% 2.9% MDXHEALTH EN Brussels 61 -45.4% -5.8% BIOCORP EN Paris 54 79.9% 12.9% MEDICREA INTERNA EN Paris 42 13.5% -10.0% EUROBIO-SCIENTIF EN Paris 41 19.1% 7.0% SUPERSONIC EN Paris 35 9.3% 0.3% MAUNA KEA TECHNO EN Paris 30 -41.3% -23.1% MAINSTAY MEDICAL EN Paris 28 n.a.
Load more

Recommended publications
  • Euro Stoxx® Multi Premia Index
    EURO STOXX® MULTI PREMIA INDEX Components1 Company Supersector Country Weight (%) SARTORIUS STEDIM BIOTECH Health Care France 1.59 IMCD Chemicals Netherlands 1.25 VOPAK Industrial Goods & Services Netherlands 1.15 BIOMERIEUX Health Care France 1.04 REMY COINTREAU Food, Beverage & Tobacco France 1.03 EURONEXT Financial Services France 1.00 HERMES INTERNATIONAL Consumer Products & Services France 0.94 SUEZ ENVIRONNEMENT Utilities France 0.94 BRENNTAG Chemicals Germany 0.93 ENAGAS Energy Spain 0.90 ILIAD Telecommunications France 0.89 DEUTSCHE POST Industrial Goods & Services Germany 0.88 FUCHS PETROLUB PREF Chemicals Germany 0.88 SEB Consumer Products & Services France 0.87 SIGNIFY Construction & Materials Netherlands 0.86 CARL ZEISS MEDITEC Health Care Germany 0.80 SOFINA Financial Services Belgium 0.80 EUROFINS SCIENTIFIC Health Care France 0.80 RATIONAL Industrial Goods & Services Germany 0.80 AALBERTS Industrial Goods & Services Netherlands 0.74 KINGSPAN GRP Construction & Materials Ireland 0.73 GERRESHEIMER Health Care Germany 0.72 GLANBIA Food, Beverage & Tobacco Ireland 0.71 PUBLICIS GRP Media France 0.70 UNITED INTERNET Technology Germany 0.70 L'OREAL Consumer Products & Services France 0.70 KPN Telecommunications Netherlands 0.68 SARTORIUS PREF. Health Care Germany 0.68 BMW Automobiles & Parts Germany 0.68 VISCOFAN Food, Beverage & Tobacco Spain 0.67 SAINT GOBAIN Construction & Materials France 0.67 CORBION Food, Beverage & Tobacco Netherlands 0.66 DAIMLER Automobiles & Parts Germany 0.66 PROSIEBENSAT.1 MEDIA Media Germany 0.65
    [Show full text]
  • Purpose & Patience
    PURPOSE & PATIENCE We aspire to be the preferred partner of entrepreneurs and families who lead growing companies by backing them with patient capital and supportive advice — Q1 2020 Edition — OUR MISSION Our goal at Sofina is to create economic value with a human approach We believe that the entrepreneurial spirit that characterises many family businesses and growth companies is a source of progress. By supporting these entrepreneurs and innovators, we intend to contribute to global growth, development and innovation. We believe entrepreneurs become successful by being competitive in a globalised market Our mission is to provide patient capital, expertise and advice to growing companies led by entrepreneurs and families. We aspire to be their preferred partner, and have a long-term horizon that few other investors can match. Our heritage and culture are what make us unique We put human relationships at the heart of what we do. All our investments are stories of shared values, friendships and ambitious projects with talented entrepreneurs and their management teams. By continuously working in this way, we aspire to become the preferred investment partner of those sharing our beliefs and vision. 2 SOFINA - PURPOSE & PATIENCE OUR MISSION 3 KEY FIGURES Highlights EUR 7.63 BN GLOBAL SHAREHOLDERS’ EQUITY REACH A FAMILY RUN 3 US EUROPE ASIA AND CONTROLLED COMPLEMENTARY Change over the last 20 INVESTMENT COMPANY INVESTMENT years (2) STYLES 8.00 7.00 6.00 5.00 FOUR FOCUS 4.00 SECTORS Long-term minority 3.00 investments 2.00 1.00 43% OF SHAREHOLDERS’ EQUITY (1) Offices in Brussels, 0 Luxembourg and Singapore Consumer and Retail 1999 2019 Sofina Private Funds – Investments in venture and growth capital funds Digital Transformation 31% OF SHAREHOLDERS’ EQUITY (1) Roots going back 26 Sofina Growth – Investments in Education investment fast-growing businesses professionals 120+ YEARS across our 20% OF SHAREHOLDERS’ EQUITY (1) 3 offices Healthcare (1) Considering the portfolio in transparency.
    [Show full text]
  • Other Financial Services Investment Research Sector Update
    Other Financial Services Investment Research Sector Update 01 March 2011 -40% 170 -35% 160 BELGIAN HOLDING AND INVESTMENT COMPANIES -30% 150 -25% 140 Last month's news flow Ackermans & van Haaren Bank Van Breda intends to launch a counter bid on ABK -20% 130 Ackermans & van Haaren Publication of flash note "FY10 preview: considerable increase of current result expected" -15% 120 Bois Sauvage Final closing of the sale of its participation in Bank Degroof -10% 110 Bois Sauvage Simplification of controlling structure - upgrade to Buy CNP/NPM Interruption of share buy-back programme -5% 100 CNP/NPM CNP/NPM portfolio company BIG is not to be sold 0% 90 Gimv Folow-up investment in NovoPolymers 90 92 94 96 98 00 02 04 06 08 10 12 Gimv 9M10/11 update Source : Bloomberg, ESN - Bank Degroof Research Gimv Divestment of Plexxikon to Daiichi Sankyo Histogram : Average (unweighted) discount to adjusted NAV of 5 largest Quest for Growth Publication of company update "FY10 release and portfolio update" holding companies (LHS) RHJ International Publication of flash note "The final settlement of the Honsel bankruptcy could turn out Line : Cumulative excess return Belgian investment companies vs. Belgian to be more favourable for RHJI than previously anticipated" All Shares Return Index since 1990 (RHS) RHJ International Refinancing of Asahi Tec's debt RHJ International Sale of stake in Niles Sector performances Abs. Perf. (1 month) -0.8% Financial calendar Abs. Perf. (3 month) 6.7% 03-Mar-11 Ackermans & van Haaren FY10 Results + analyst meeting 03-Mar-11
    [Show full text]
  • Fact Sheet As of 06/30/2021
    iShares MSCI Belgium ETF EWK Fact Sheet as of 06/30/2021 The iShares MSCI Belgium ETF seeks to track the investment results of a broad-based index composed of Belgian equities. KEY FACTS Fund Launch Date 03/12/1996 Expense Ratio 0.51% WHY EWK? Benchmark MSCI Belgium IMI 25/50 1 Exposure to a broad range of companies in Belgium Index 2 Targeted access to Belgian stocks 30 Day SEC Yield 1.26% Number of Holdings 45 3 Use to express a single country view Net Assets $42,175,764 Ticker EWK GROWTH OF 10,000 USD SINCE INCEPTION CUSIP 464286301 Exchange NYSE Arca TOP HOLDINGS (%) ANHEUSER BUSCH INBEV SA 21.73 KBC GROEP 9.11 ARGENX 6.71 UCB SA 6.40 GROUPE BRUXELLES LAMBERT NV 4.60 UMICORE SA 4.56 SOLVAY SA 4.25 Fund Benchmark AGEAS SA 3.94 The Growth of $10,000 chart reflects a hypothetical $10,000 investment and assumes SOFINA SA 3.36 reinvestment of dividends and capital gains. Fund expenses, including management fees and WAREHOUSES DE PAUW NV 2.63 other expenses were deducted. 67.29 PERFORMANCE Holdings are subject to change. 1 Year 3 Year 5 Year 10 Year Since Inception NAV 35.40% 5.77% 7.10% 7.56% 5.81% Market Price 35.81% 6.06% 7.06% 7.57% 5.82% Benchmark 29.34% 4.17% 6.10% 7.91% 5.85% The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than the original cost.
    [Show full text]
  • Company Profile
    COMPANY PROFILE - October 2015 - GENERAL OVERVIEW MISSION & VALUES Sofina is a European, family-controlled, investment Our Mission company listed on Euronext Brussels. To provide patient and supportive Market Capitalization* : € 3.4 Bn capital helping families and entrepreneurs to develop their Net Asset Value* : € 4.9 Bn businesses Offices in Brussels, Luxemburg & Singapore Our Values A team of 51 professionals across our offices Entrepreneurial talent and families are a major driver of progress and Website: www.sofina.be innovation globally. Sofina’s mission (* Jun 2015, excl. own shares) is… … to foster the long-term growth of 3 MAIN LINES OF BUSINESS their endeavors … to provide, directly or indirectly, with 1. Long term strategic minority investments (~65%) patient capital and value-added support tailored to their specific needs 2. Investments in top tier Private Equity Funds (~25%) … to become the preferred partner of every like-minded family or 3. Co-investments in fast growing businesses (<10%) entrepreneur in the investment business 1 I. LONG TERM STRATEGIC INVESTMENTS INVESTMENT PHILOSOPHY MAIN HOLDINGS Minority investor (€ 75-200 M equity tickets) Long term view Active and supportive Board participation Public or private corporations Diversified sector base Primarily European based companies 2 II. ALTERNATIVE INVESTMENTS - PRIVATE EQUITY/VENTURE CAPITAL FUNDS INVESTMENT PHILOSOPHY MAIN PARTNERS USA (70%) Long-term partnerships with leading funds Focus on Venture and Expansion Capital Predominantly US-based EMERGING MARKETS (15%) funds (activity started in the US in the late 70s) EUROPE (15%) 3 III. CO-INVESTMENTS - VENTURE, GROWTH & BUY-OUT INVESTMENT PHILOSOPHY VENTURE & GROWTH COMPANIES MAIN PARTNERS Minority investor ($ 15-50 M equity tickets) Round led by a trusted partner F&B Focus on high-growth sectors (incl.
    [Show full text]
  • Fidelity® International Index Fund
    Quarterly Holdings Report for Fidelity® International Index Fund November 30, 2020 SPI-QTLY-0121 1.810719.116 Schedule of Investments November 30, 2020 (Unaudited) Showing Percentage of Net Assets Common Stocks – 97.1% Shares Value Shares Value Australia – 6.6% Washington H. Soul Pattinson & Co. Ltd. 203,862 $ 4,345,688 Afterpay Ltd. (a) 409,961 $ 28,591,537 Wesfarmers Ltd. 2,182,329 79,215,864 AGL Energy Ltd. 1,210,067 11,991,371 Westpac Banking Corp. 6,949,073 101,905,324 AMP Ltd. 6,559,158 8,233,222 WiseTech Global Ltd. 279,599 6,341,905 Ampol Ltd. 474,005 10,664,464 Woodside Petroleum Ltd. 1,845,417 30,303,036 APA Group unit 2,255,752 17,137,890 Woolworths Group Ltd. 2,432,680 66,035,510 Aristocrat Leisure Ltd. 1,100,616 25,901,504 ASX Ltd. 370,987 20,998,827 TOTAL AUSTRALIA 1,959,645,611 Aurizon Holdings Ltd. 3,707,573 11,566,562 Australia & New Zealand Banking Group Ltd. 5,458,203 90,709,286 Austria – 0.2% BHP Billiton Ltd. 5,669,746 158,108,139 Erste Group Bank AG 533,942 15,320,260 BlueScope Steel Ltd. 965,128 12,114,533 OMV AG 280,917 9,406,520 Brambles Ltd. 2,908,146 23,396,581 Raiffeisen International Bank‑Holding AG 278,553 5,314,896 Cimic Group Ltd. (a) 184,902 3,470,547 Verbund AG 130,252 9,154,254 Coca‑Cola Amatil Ltd. 972,096 9,026,623 Voestalpine AG 221,319 7,089,483 Cochlear Ltd.
    [Show full text]
  • 2020 Annual Report
    DECEMBER 31, 2020 2020 Annual Report BlackRock Funds III • iShares MSCI Total International Index Fund Not FDIC Insured • May Lose Value • No Bank Guarantee The Markets in Review Dear Shareholder, The 12-month reporting period as of December 31, 2020 has been a time of sudden change in global financial markets, as the emergence and spread of the coronavirus (or “COVID-19”) led to a vast disruption in the global economy and financial markets. The threat from the coronavirus became increasingly apparent throughout February and March 2020, and countries around the world took economically disruptive countermeasures. Stay-at-home orders and closures of non-essential businesses became widespread, many workers were laid off, and unemployment claims spiked, causing a global recession and a sharp fall in equity prices. After markets hit their lowest point of the reporting period in late March 2020, a steady recovery ensued, as businesses began to re-open and governments learned to adapt to life with the virus. Equity prices continued Rob Kapito to rise throughout the summer, fed by strong fiscal and monetary support and improving economic indicators. President, BlackRock Advisors, LLC Many equity indices neared or surpassed all-time highs late in the reporting period following a series of successful vaccine trials and passage of additional stimulus. In the United States, both large- and small- capitalization stocks posted a significant advance. International equities from developed economies grew at a more modest pace, lagging emerging market stocks, which rebounded sharply. Total Returns as of December 31, 2020 6-Month 12-Month During the market downturn, the performance of different types of fixed-income securities initially diverged due U.S.
    [Show full text]
  • FACTSHEET - AS of 24-Sep-2021 Solactive GBS Belgium Large & Mid Cap Index TR
    FACTSHEET - AS OF 24-Sep-2021 Solactive GBS Belgium Large & Mid Cap Index TR DESCRIPTION The Solactive GBS Belgium Large & Mid Cap Index TR is part of the Solactive Global Benchmark Series which includes benchmark indices for developed and emerging market countries. The index intends to track the performance of the large and mid cap segment covering approximately the largest 85% of the free-float market capitalization in the Belgian market. It is calculated as a total return indexinEUR and weighted by free-float market capitalization. HISTORICAL PERFORMANCE 1,000 900 800 700 600 500 400 300 200 Jan-2008 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Jan-2022 Solactive GBS Belgium Large & Mid Cap Index TR CHARACTERISTICS ISIN / WKN DE000SLA4DC5 / SLA4DC Base Value / Base Date 725.02 Points / 08.05.2006 Bloomberg / Reuters / .SBELMCT Last Price 831.43 Index Calculator Solactive AG Dividends Reinvested Index Type Total Return Calculation 8:00 am to 10:30 pm (CET), every 15 seconds Index Currency EUR History Available daily back to 08.05.2006 Index Members 16 FACTSHEET - AS OF 24-Sep-2021 Solactive GBS Belgium Large & Mid Cap Index TR STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -3.37% -5.85% 5.20% 20.82% 6.01% 14.68% Performance (p.a.) - - - - - 0.89% Volatility (p.a.) 11.25% 13.27% 12.79% 17.52% 14.21% 22.53% High 863.93 878.49 901.39 901.39 901.39 1007.16 Low 813.25 813.25 797.43 650.18 749.91 203.19 Sharpe Ratio -2.98 -1.59 0.89 1.24 0.62 0.06 Max.
    [Show full text]
  • Purpose & Patience
    Purpose & Patience We aspire to be the preferred partners of entrepreneurs and families who lead growing companies by backing them with patient capital and supportive advice. — H1 2019 Edition — 1 1 Our mission Our goal at Sofina is to create economic value with a human face. We believe that the entrepreneurial spirit that characterises many family businesses and growth companies is a source of progress. By supporting these entrepreneurs and innovators, we intend to contribute to global growth, development and innovation. We believe entrepreneurs become successful by being competitive in a globalized market. Our mission is to provide patient capital, expertise and advice to growing companies led by entrepreneurs and families and aspire to be their preferred partner, coupled with a long-term horizon that few other investors can match. Our heritage and culture are what makes us unique. We put human relationships at the heart of what we do. All our investments are stories of shared values, friendships and ambitious projects with talented entrepreneurs and their management teams. By continuously working this way, we aspire to become the preferred investment partner for all those who share our beliefs and vision. 2 | Sofina | Purpose & Patience 3 | Our mission Highlights 2 ~€ 5 bn Global reach net6. asset value6 * A family run 3 US Europe Asia and controlled complementary investment Change over the last 20 years (1) investment company pillars 6.56 6.75 6.00 5.25 4.50 Four focus sectors 3.75 Long-term minority 3.00 1.70 investments 2.25 1.50 Offices in % NAV * 0.75 46 0 Brussels, Luxembourg Consumer 1997 2H2018 and Singapore Investments in venture and growth capital funds Digital 30% NAV * Roots going back ~ 5 Education Sofina Growth ─ 2 Investments in fast-growing investment businesses professionals * 120 Healthcare 17% NAV years across our 3 offices (1) Shareholders’ equity is net asset value as from 2017.
    [Show full text]
  • Sofina Announces the Launch of the Sale of Its Stake in Eurazeo
    NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA Press release Sofina announces the launch of the sale of its stake in Eurazeo Brussels, Belgium, April 18, 2017 at 5.45 pm – Sofina today announces the launch of the sale of c.3.5m shares of Eurazeo, representing approximately 5% of the share capital, by way of an accelerated bookbuilding reserved to institutional investors (the “Placement”). Sofina will no longer hold any Eurazeo shares after the transaction. As part of its share buyback program, Eurazeo will participate in the Placement with a 1.0 million shares irreducible order at the Placement price. The definitive terms of the Placement will be determined following the completion of the bookbuilding process. The bookbuilding will commence immediately and will be managed by Société Générale Corporate & Investment Banking, Sole Bookrunner on the transaction. Disclaimer No communication and no information in respect of the sale described in this announcement may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken in any jurisdiction where such steps would be required. The Placement described in this announcement may be subject to specific legal or regulatory restrictions in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to solicit the interest of the public in France, the United States, or in any other jurisdiction, in connection with any offer.
    [Show full text]
  • Global Equity Holdings As of June 30, 2021
    New York State Teachers' Retirement System Global Equity Holdings As of June 30, 2021 Security Name Shares Market Value 21VIANET GROUP INC ADR 29,980 688,041 360 DIGITECH INC 30,130 1,260,639 360 SECURITY TECHNOLOGY IN A 58,900 111,301 3I GROUP PLC 939,470 15,223,557 3M CO 3,460 687,260 3SBIO INC 486,500 601,402 51JOB INC ADR 10,930 850,026 908 DEVICES INC 34,264 1,327,730 A LIVING SMART CITY SERVICES 156,500 778,888 A2 MILK CO LTD 274,081 1,233,351 A2A SPA 3,687,145 7,538,341 AAC TECHNOLOGIES HOLDINGS IN 255,009 1,907,843 AAREAL BANK AG 57,400 1,325,336 ABACUS PROPERTY GROUP 111,744 264,259 ABB LTD REG 611,612 20,769,731 ABB LTD SPON ADR 129,800 4,411,902 ABBOTT LABORATORIES 7,779 901,819 ABBVIE INC 74,900 8,436,736 ABC MART INC 16,700 958,456 ABCAM PLC 868,868 16,576,113 ABDULLAH AL OTHAIM MARKETS 17,087 564,950 ABN AMRO BANK NV CVA 404,007 4,883,111 ABOITIZ EQUITY VENTURES INC 623,000 537,938 ABRDN PLC 1,273,769 4,768,647 ABSA GROUP LTD 498,682 4,739,989 ABU DHABI COMMERCIAL BANK 970,467 1,815,093 ABU DHABI ISLAMIC BANK 32,746 48,854 ABU DHABI NATIONAL OIL CO FO 848,585 1,000,333 ACADIA REALTY TRUST 16,426 360,715 ACCENT GROUP LTD 202,886 424,964 ACCENTURE PLC CL A 126,880 37,402,955 ACCOR SA 210,296 7,853,296 ACCTON TECHNOLOGY CORP 192,000 2,277,470 ACER INC 1,052,526 1,106,829 ACOM CO LTD 148,100 645,828 ACS ACTIVIDADES CONS Y SERV 84,882 2,273,946 ACS ACTIVIDADES DE CONSTRUCCIO 84,882 118,781 ACTIVIA PROPERTIES INC 703 3,331,633 ACTIVISION BLIZZARD INC 824 78,643 ACUITY BRANDS INC 2,940 549,868 ADANI ENTERPRISES LTD 85,862 1,740,805
    [Show full text]
  • Benelux Holding & Portfolio Companies
    Hans D’Haese Holding & portfolio companies Sell-side equity analyst Benelux What is the added value? Luxembourg, 14/06/16 Holding & portfolio companies Added value Diversification – Risk – Return Luxembourg, 14/06/16 Added value of holding & portfolio companies Sector peculiarities Universe. What does this sector look like? Valuation. What is it worth? What’s the risk? How did it perform? What to do? 3 Luxembourg, 14/06/16 Holding & portfolio companies 1. Sector peculiarities Luxembourg, 14/06/16 1 Added value of holding & portfolio companies Sector peculiarities Control • Economic interest leverage • Execute control with a diluted participation Diversification • From very well diversified… • … to single-asset companies Taxes • Exempt on capital gains • Most of dividends: no with-holding tax • Related costs to shareholdings fully tax deductible 5 Luxembourg, 14/06/16 Holding & portfolio companies 2. What does the sector look like? Luxembourg, 14/06/16 2 Added value of holding & portfolio companies Universe 7 Luxembourg, 14/06/16 2 Added value of holding & portfolio companies Universe Holding company Industrial group Portfolio company Singe-asset company control diversification investment company anchorage 8 Luxembourg, 14/06/16 2 Added value of holding & portfolio companies Universe Holding companies GBL / CNP / … Sofina / Henex / … Compagnie du Bois Sauvage • Business segments are organised within an independent firm (< > conglomerate) • Gradually shifting from controlling structure to investment company 9 Luxembourg, 14/06/16 2 Added
    [Show full text]